Scolaris Content Display Scolaris Content Display

Cochrane Database of Systematic Reviews

Azitromicina para el tratamiento del paludismo no complicado

Información

DOI:
https://doi.org/10.1002/14651858.CD006688.pub2Copiar DOI
Base de datos:
  1. Cochrane Database of Systematic Reviews
Versión publicada:
  1. 16 febrero 2011see what's new
Tipo:
  1. Intervention
Etapa:
  1. Review
Grupo Editorial Cochrane:

  1. Grupo Cochrane de Enfermedades infecciosas

Clasificada:
  1. Actualización no planificada

    Other

    This not a current research question: please see the authors' conclusions section of the review

    Evaluada: 8 May 2019

Copyright:
  1. Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Cifras del artículo

Altmetric:

Citado por:

Citado 0 veces por enlace Crossref Cited-by

Contraer

Autores

  • Anna M van Eijk

    Correspondencia a: Child & Reproductive Health Group, Liverpool School of Tropical Medicine, Liverpool, UK

    [email protected]

  • Dianne J Terlouw

    Child & Reproductive Health Group, Liverpool School of Tropical Medicine, Liverpool, UK

Contributions of authors

AM van Eijk wrote the protocol and review. DJ Terlouw edited the protocol and review, and assisted with the gathering of data.

Sources of support

Internal sources

  • No sources of support supplied

External sources

  • Nuffield Commonwealth Foundation, UK.

  • Department for International Development (DFID), UK.

  • Liverpool School of Tropical Medicine, UK.

Declarations of interest

None known.

Acknowledgements

A M van Eijk was awarded a Reviews for Africa Programme Fellowship (www.mrc.ac.za/cochrane/rap.htm), funded by a grant from The Nuffield Commonwealth Programme, through The Nuffield Foundation. D J Terlouw received financial support from the Centers for Disease Control. The editorial base for the Cochrane Infectious Diseases Group is funded by the UK Department for International Development for the benefit of developing countries.

We are grateful to Dr R Chandra from Pfizer for additional information on Pfizer‐led trials, and to Dr Noedl and Dr Thriemer for their kind assistance in providing additional information. We thank Dr Gertrude Kalanda for her help in verifying trial information, and Professor F ter Kuile for his review of the manuscript.

Version history

Published

Title

Stage

Authors

Version

2011 Feb 16

Azithromycin for treating uncomplicated malaria

Review

Anna M van Eijk, Dianne J Terlouw

https://doi.org/10.1002/14651858.CD006688.pub2

2007 Jul 18

Azithromycin for treating uncomplicated malaria

Protocol

Anna M van Eijk, Dianne J Terlouw

https://doi.org/10.1002/14651858.CD006688

Differences between protocol and review

Although we initially intended to assess the possibility of subgroup analysis by species of malaria, it proved irrelevant to compare studies for P. vivax directly with studies for P. falciparum given the different efficacy of the drugs used for these species. We decided instead to keep all data stratified by malaria species. The trials excluded for meta‐analyses were included in the assessment of adverse events and drug efficacy, because they provided valuable information for these outcomes. We believe that excluding these trials would deprive the reader of a complete overview of the topic. This review was conducted over several years and because of the adoption of new methods by the Cochrane group for assessing risk of bias, we changed our assessment accordingly using the revised guidelines in 2008.